Navigation Links
New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease
Date:1/21/2013

KING OF PRUSSIA, Pa., Jan. 21, 2013 /PRNewswire/ -- Treatment with albumin reduces renal impairment and mortality in cirrhotic patients with spontaneous bacterial peritonitis (SBP), one of the most common bacterial infections in this patient population, according to a new meta-analysis supported by CSL Behring and published today in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association Institute. Albumin, a natural plasma-derived protein that expands blood plasma volume, is widely used in conjunction with large-volume paracentesis to treat tense ascites, with vasoconstrictors for type 1 hepatorenal syndrome and with antibiotics for SBP.

"While current clinical guidelines indicate the benefits of albumin for patients with SBP, questions regarding patient selection and albumin dosing in the management of the condition still linger," said Francesco Salerno , M.D., Professor of Internal Medicine at the University of Milan in Italy, and lead author of the meta-analysis. "Based on our quantitative findings and the clear benefits demonstrated, it seems prudent to treat all SBP patients with albumin, regardless of whether they are high-risk or low-risk for poor outcome."

SBP occurs without any obvious source of intra-abdominal infection. Several factors are believed to contribute to SBP including bacterial overgrowth in the intestine, passage of the bacteria across an impaired intestinal barrier into the blood stream and abdominal cavity, and a deficient local immune response to the invasion. Renal impairment, a frequent complication of SBP, is associated with high risk of mortality, which may reach 30% despite prompt treatment.

The meta-analysis, which included results from four randomized controlled trials with 288 total patients, found that SBP patients treated with albumin were less likely to develop renal impairment (8.3 percent in the albumin-treated groups versus 30.6 percent in the control groups). The odds ratios for renal impairment in the four trials were highly consistent, ranging from 0.19 to 0.30. The analysis also found that mortality was decreased with albumin administration (16 percent in the albumin-treated groups versus 35.4 percent in the control groups). Odds ratios for mortality were also similar, ranging from 0.16 to 0.55.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.  CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company with headquarters in Melbourne, Australia. For more information visit http://www.cslbehring.com. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.

Contact:
Sheila A. Burke , Director, Communications & Public Relations
Worldwide Commercial Operations
CSL Behring
610-878-4209 (o)
484-919-2618 (c)
Sheila.Burke@cslbehring.com


'/>"/>
SOURCE CSL Behring
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
2. Valeritas Announces The Publication Of A Retrospective Analysis Of Patient-Reported Data On The V-Go In The Current Issue Of Endocrine Practice
3. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
4. Analysis Finds Improvements in Health-Related Quality of Life for Hereditary Angioedema Patients Treated with C1-Inhibitor
5. Convenient New iHealth Blood Pressure Monitors and Body Analysis Scale Now Available for Purchase at Major Retailers and Online
6. Leavitt Partners Health Reform Bracketology analysis considers impact of U.S. elections on the Affordable Care Act
7. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
8. Generics Analysis: Key Patent Case Reviews
9. Reliance Pharmaceuticals: Biosimilars Company Analysis
10. US Cancer Vaccine Market Analysis
11. New Analysis Shows Illicit Drug Use May Vary by Payer Type: Detection Rates as High as 17 Percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... as president, effective Aug. 7, 2017. ... to pursue other interests and will serve as president emeritus ... has served us in multiple leadership roles since he joined ... 2015 and has provided decisive, strategic leadership which continues to ...
(Date:8/3/2017)... -- Opioid addiction and other drugs of abuse, blood poisoning ... outcomes, were problems taken on directly as laboratory professionals, ... them, met this week. This according to Kalorama Information. ... abuse, procalcitonin and acute kidney injury were key focuses ... in San Diego, CA.  Mechanisms ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5 ... , The healthcare industry in the United States has undergone major changes over the ... needing to have a doctor’s order to get a blood test or other lab ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... August 16, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, Prache ... effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , “Prache ...
(Date:8/16/2017)... ... ... Chain”: an inspirational story for those shackled by the chains of a broken life. ... writer and a woman of great faith and wisdom. She is a great motivational ... born and raised in Vero Beach, Florida and has dedicated her life and ministry to ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... of disease. It’s reaching out to a patient who feels isolated. It’s developing ... amid madness. , WesternU President Daniel R. Wilson, MD, PhD, invited three renowned ...
Breaking Medicine News(10 mins):